molecules of the month


oral, allosteric PRC2 inhibitor (EED)

Ph. Ib for sickle cell disease (on hold)

VLS, FBLD, de novo design + opt.

Press release, February 24, 2023

Fulcrum Therapeutics, Cambridge, MA

pociredir, oral, allosteric PRC2 inhibitor (EED), Ph. IIb for sickle cell disease (on hold), FULCRUM THERAPEUTICS
9 mins read

Induction of fetal hemoglobin expression by a PRC-targeting small molecule. Pociredir (FTX-6058) is an oral, allosteric polycomb repressive complex 2 (PRC2) inhibitor that binds embryonic ectoderm development protein (EED) within this complex, ultimately boosting fetal hemoglobin (HbF) expression. Increasing HbF levels has been shown to mitigate the mortality and morbidity risks of Sickle Cell Disease (SCD), which are caused by mutations in the adult hemoglobin HBB gene. As a small molecule treatment, this macrocyclic azolopyridine distinguishes itself in a therapeutic area dominated by gene-correction candidates. For chemists, it is a notable example of a 9-membered macrocycle with relatively high ring strain (~15.5 kcal/mol) that has entered clinical development.  The first clinical EED1 inhibitor for sickle cell disease. In recent years,…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: